{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-26-000048","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2026-05-27T21:13:33+00:00","discovered_at":"2026-05-27T21:16:00.263705+00:00","generated_at":"2026-05-27T21:19:35.305862+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Biohaven reports positive clinical data for opakalim in epilepsy and BHV-1300/BHV-1400 in autoimmune diseases at R&D Day","bullets":["Opakalim 75 mg prolonged median time to second seizure to 141 days vs 47 days for placebo in idiopathic generalized epilepsy trial.","54% of focal epilepsy patients on opakalim achieved ≥50% seizure reduction over six months in open-label extension.","BHV-1300 reduced pathogenic TSHR-IgG1 >80% by week 12 and normalized thyroid hormones within weeks in Graves' disease patients.","BHV-1400 reduced Gd-IgA1 >60% within hours and 70% within one month in IgA nephropathy, with early eGFR and UPCR improvements.","Both degrader programs showed well-tolerated safety profiles with no serious adverse events; pivotal Phase 3 trials expected to initiate mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-26-000048","json":"https://secwatch.observer/filing/0001935979-26-000048.json","markdown":"https://secwatch.observer/filing/0001935979-26-000048.md","text":"https://secwatch.observer/filing/0001935979-26-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597926000048/0001935979-26-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597926000048/bhvn-20260526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-27T21:19:35.305862+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001193125-26-251399","ticker":"IDYA","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2026-06-01T20:05:32+00:00","headline":"IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251399","json":"https://secwatch.observer/filing/0001193125-26-251399.json","markdown":"https://secwatch.observer/filing/0001193125-26-251399.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/0001193125-26-251399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/d138848d8k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063486","ticker":"MDAI","company_name":"Spectral AI, Inc.","filed_at":"2026-06-01T20:01:42+00:00","headline":"Spectral AI gets FDA clearance for DeepView burn indication; targets first commercial sales by year-end 2026","event_type":"other_material","sec_items":["5.07","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063486","json":"https://secwatch.observer/filing/0001213900-26-063486.json","markdown":"https://secwatch.observer/filing/0001213900-26-063486.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833498/000121390026063486/0001213900-26-063486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833498/000121390026063486/ea0292962-8k_spectral.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026544","ticker":"LIXT","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2026-06-01T12:55:34+00:00","headline":"Lixte Biotechnology pivots to AI energy infrastructure; appoints Denham Capital founder to board","event_type":"other_material","sec_items":["5.02","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026544","json":"https://secwatch.observer/filing/0001493152-26-026544.json","markdown":"https://secwatch.observer/filing/0001493152-26-026544.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063161","ticker":"OPTU","company_name":"Optimum Communications, Inc.","filed_at":"2026-06-01T12:16:33+00:00","headline":"Optimum raises $500M via preferred units, starts $300M tender at $2.50 to shield assets from CSC debt","event_type":"other_material","sec_items":["1.01","3.02","7.01","8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063161","json":"https://secwatch.observer/filing/0001213900-26-063161.json","markdown":"https://secwatch.observer/filing/0001213900-26-063161.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1702780/000121390026063161/0001213900-26-063161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1702780/000121390026063161/ea0292871-8k_optimum.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063157","ticker":"JSPR","company_name":"Jasper Therapeutics, Inc.","filed_at":"2026-06-01T12:01:20+00:00","headline":"Jasper Therapeutics initiates strategic review including potential sale or wind-down","event_type":"other_material","sec_items":["7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063157","json":"https://secwatch.observer/filing/0001213900-26-063157.json","markdown":"https://secwatch.observer/filing/0001213900-26-063157.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026063157/0001213900-26-063157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026063157/ea0292909-8k_jasper.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-249725","ticker":"EIKN","company_name":"Eikon Therapeutics, Inc.","filed_at":"2026-06-01T11:30:25+00:00","headline":"Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-249725","json":"https://secwatch.observer/filing/0001193125-26-249725.json","markdown":"https://secwatch.observer/filing/0001193125-26-249725.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526249725/0001193125-26-249725-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526249725/eikn-20260530.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251394","ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2026-06-01T20:05:16+00:00","headline":"Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251394","json":"https://secwatch.observer/filing/0001193125-26-251394.json","markdown":"https://secwatch.observer/filing/0001193125-26-251394.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/0001193125-26-251394-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/fulc-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001628280-26-039297","ticker":"GPRO","company_name":"GoPro, Inc.","filed_at":"2026-06-01T13:12:22+00:00","headline":"GoPro refiles financials with going-concern warning; potential defaults on debt","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same SEC item: 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039297","json":"https://secwatch.observer/filing/0001628280-26-039297.json","markdown":"https://secwatch.observer/filing/0001628280-26-039297.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500435/000162828026039297/0001628280-26-039297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500435/000162828026039297/gpro-20260601.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}